| 000 | 01403na a2200229 4500 | ||
|---|---|---|---|
| 003 | PC8209 | ||
| 005 | 20210702062700.0 | ||
| 008 | 130622s2013 xxx||||| |||| 00| 0 eng d | ||
| 040 | _cH12O | ||
| 041 | _aeng | ||
| 100 |
_91026 _aPulido Ortega, Federico _eUnidad VIH |
||
| 245 | 0 | 0 |
_aSwitching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine. _h[artÃculo] |
| 260 |
_bThe Journal of antimicrobial chemotherapy, _c2013 |
||
| 300 | _a68(6):1373-81. | ||
| 500 | _aFormato Vancouver: Bernardino JI, Pulido F, MartÃnez E, Arrizabalaga J, Domingo P, Portilla J et al. GESIDA-6008-KRETA Study Group. Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine. J Antimicrob Chemother. 2013 Jun;68(6):1373-81. | ||
| 501 | _aPMID: 23386261 | ||
| 504 | _aContiene 31 referencias | ||
| 520 | _aBACKGROUND: Discontinuation of thymidine nucleoside reverse transcriptase inhibitors (tNRTIs) is the only proven strategy for improving lipoatrophy. It is unclear whether switching to NRTI-sparing or to non-thymidine NRTI-containing therapy has differential effects on body fat recovery. | ||
| 710 |
_96 _aServicio de Medicina Interna |
||
| 856 |
_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/8/pc8209.pdf _ySolicitar documento |
||
| 942 |
_n0 _2ddc _cART |
||
| 999 |
_c8209 _d8209 |
||